ruxolitinib

all catalysts(1)

News(8)

• Incyte cuts early-stage cancer drug to focus on next-gen programs
  Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
  biospace · 23d ago
• Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
  Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.
  fiercebiotech · 24d ago
• Lilly scores early positive data for new JAK drug
  Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
  biopharma_dive · 2mo ago
• Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
  Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…
  endpoints · 2mo ago
• Incyte to buy blood disorder drug in possibly $2B deal
  Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
  biopharma_dive · 2mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 3mo ago
• Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
  Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
  onclive · 3mo ago
• Lilly to buy startup Ajax in bid for a better JAK drug
  Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
  biopharma_dive · 3mo ago